| Aminda Skan, PHARMD | |
|
4320 Diplomacy Dr Ste 1203, Anchorage, AK 99508-5925 | |
| (907) 729-1742 | |
| Not Available |
| Full Name | Aminda Skan |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 4320 Diplomacy Dr Ste 1203, Anchorage, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508534637 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 178772 (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Aminda Skan, PHARMD 4320 Diplomacy Dr Ste 1203, Anchorage, AK 99508-5925 Ph: (907) 729-1742 | Aminda Skan, PHARMD 4320 Diplomacy Dr Ste 1203, Anchorage, AK 99508-5925 Ph: (907) 729-1742 |
News Archive
Hemophilia is a bleeding disorder that, if untreated, causes recurrent bleeding into joints. "Vigorous physical activity is thought to increase risk of bleeds in children with hemophilia, but the magnitude of the risk is unknown," according to background information in the article. Information about risks associated with physical activity is needed to help inform decisions regarding participation in physical activity, the authors write.
A new blood test which uses microchip technology may offer doctors the opportunity to detect cancers earlier and also monitor cancer treatment.
Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, today announced the closing of a EUR 15 Million financing, bringing the total equity funding raised by the company to EUR 57.4 Million (USD 84 Million) since it's foundation in 2006.
The U.S. Food and Drug Administration today granted final approval of the first generic naloxone hydrochloride nasal spray, commonly known as Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
› Verified 3 days ago
Ciara M Smith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1650 W Northern Lights Blvd, Pharmacy Dept, Anchorage, AK 99517 Phone: 907-339-0560 | |
Kelly Cutrer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12045 Brandon St, Anchorage, AK 99515 Phone: 907-631-0300 Fax: 907-631-0632 | |
Dr. Kyle Patrick Smith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 673 Mdg / Sghq, 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-2778 | |
Dr. Remi Cristen Williamson, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-2117 | |
Evan Michael Ambrose, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1650 W Northern Lights Blvd, Anchorage, AK 99517 Phone: 907-339-0560 | |
Timothy Paul Stone, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1200 N Muldoon Rd, Anchorage, AK 99504 Phone: 907-332-1004 | |
Jordan E Bell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3260 Providence Dr Ste C520, Anchorage, AK 99508 Phone: 907-212-3420 Fax: 907-212-3429 |